67 related articles for article (PubMed ID: 8630232)
1. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.
Sutkowski DM; Audia JE; Goode RL; Hsiao KC; Leibovitch IY; McNulty AM; Neubauer BL
Prostate Suppl; 1996; 6():62-6. PubMed ID: 8630232
[TBL] [Abstract][Full Text] [Related]
2. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
3. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
He D; Falany CN
Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
[TBL] [Abstract][Full Text] [Related]
6. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
Mizokami A; Koh E; Izumi K; Narimoto K; Takeda M; Honma S; Dai J; Keller ET; Namiki M
Endocr Relat Cancer; 2009 Dec; 16(4):1139-55. PubMed ID: 19608712
[TBL] [Abstract][Full Text] [Related]
8. Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells.
Lo S; King I; Alléra A; Klingmüller D
Toxicol In Vitro; 2007 Apr; 21(3):502-8. PubMed ID: 17218080
[TBL] [Abstract][Full Text] [Related]
9. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
10. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
[TBL] [Abstract][Full Text] [Related]
11. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells.
Xi SC; Tam PC; Brown GM; Pang SF; Shiu SY
J Pineal Res; 2000 Oct; 29(3):172-83. PubMed ID: 11034115
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
13. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
14. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
15. Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells.
Kaefer M; Audia JE; Bruchovsky N; Goode RL; Hsiao KC; Leibovitch IY; Krushinski JH; Lee C; Steidle CP; Sutkowski DM; Neubauer BL
J Steroid Biochem Mol Biol; 1996 May; 58(2):195-205. PubMed ID: 8809201
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs.
Farid NA; Schreiner KM; Coleman NL; Van Lier RB; Wrighton SA
Drug Metab Dispos; 1996 Oct; 24(10):1162-5. PubMed ID: 8894520
[TBL] [Abstract][Full Text] [Related]
17. Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.
Takizawa I; Nishiyama T; Hara N; Hoshii T; Ishizaki F; Miyashiro Y; Takahashi K
Cancer Lett; 2010 Nov; 297(2):226-30. PubMed ID: 20831980
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
20. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]